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Abstract:
This project focuses on the development of a protocol to increase administration and
documentation of pneumococcal vaccination among patient 65 years and older in a primary care
practice setting. The project entails reviewing immunization records of all patients age ≥ 65
years at Appletree Bay Primary Care (ABPC) practice to determine current pneumococcal
vaccination rates among the specified age group within the practice. A single trial vaccination
clinic was it established in collaboration with the Vermont Family Pharmacy wherein patients
were contacted by phone by the primary investigator, informed that they may be due for one or
more pneumococcal vaccination and asked if they would like to schedule an appointment for that
vaccination. The pharmacy was responsible for ordering administering and billing for
vaccinations, while the practice was responsible for calling patients 65 and older in need of one
or more pneumococcal vaccinations. The pharmacy then reported all administered vaccines back
to ABPC. Data obtained will be analyzed to determine the effectiveness of this protocol in
increasing the rate of administration and documentation of pneumococcal vaccines in ABPC
patients 65 and older.
Keywords: Pneumococcal vaccination
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Chapter I: Introduction
A.

Project purpose
The purpose of this project is to increase pneumococcal vaccination rates among patients

65 and older in a small, semi-independent Nurse Practitioner led patient focused medical home.
There is a large body of research on the causes of poor adherence to adult vaccination
recommendations in the U.S. and on strategies to improve adherence, in the form of practice
based vaccination campaigns or toolkits, but little research has focused on the problem in the
context of small practices for whom offering adult vaccinations is cost prohibitive. For such
small practices, changes to Medicare billing and reimbursement have created a system whereby
providing vaccination services to patients may result in a financial loss for the practice.
Pneumococcal disease is a common cause of illness and death in older adults, accounting
for greater morbidity than any other vaccine-preventable bacterial disease (CDC, 1997). A 2016
representative cross-sectional study by Klett-Tammen, et al. found that invasive pneumococcal
disease (IPD) outcomes are strongly associated with greater severity and fatality in older age
(Klett-Tammen, et al., 2016). Pneumococcal pneumonia is the most common clinical
presentation of pneumococcal disease in adults, with the CDC estimating approximately 900,000
cases and 400,000 hospitalizations in the United States annually (CDC, 2015). Further, mortality
rates for community-acquired pneumonia among older adults are estimated as high as 30%, with
certain subpopulations, such as nursing home residents, with rates as high as 57% (Janssen and
Krause, 2004). The severity and burden of pneumonia among older adults is largely explained
the increased occurrence of several risk factors, such as the increased incidence of comorbidities,
especially those affecting the lung parenchyma or immune system, and the high rate of
polypharmacy among this population (Janssens and Krause, 2004).
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While the morbidity and economic burden of pneumococcal illness among adults ≥65 is
well established, pneumococcal vaccination coverage among older adults was estimated at
61.3% in 2014 (Williams, et al, 2015). This figure is well below the HealthyPeople 2020 goal of
90% vaccination rate among this population. Further, despite the recommendation since 1997
that all adults ≥65 years receive vaccination against pneumococcal disease and that
pneumococcal vaccination is fully covered by Medicare Part B, more than a third of U.S. adults
65 years and older remain unvaccinated.
Estimated proportion of U.S. adults ≥65 who received pneumococcal vaccines 2010-2014,
National Health Interview Survey, United States.
Pneumococcal vaccination
rate among U.S. adults ≥65

2010
59.7

2011
62.3

2012
59.9

2013
59.7

2014
61.3

Un-weighted sample size (2010-2014): 34,640; Linear trend test p-value: 0.77 (Williams, et al., 2016).

In 2014, the Advisory Committee on Immunization Practices (ACIP) revised a previous
2012 routine adult vaccination recommendation to include the sequential administration of two
pneumococcal vaccines: pneumococcal conjugate, Prevnar13® (PCV13) and polysaccharide
vaccine Pneumonvax® (PPSV23), for all adults ≥ 65 years (Chen, et al., 2014). The rationale
behind the 2014 recommendation grew out of a preponderance of evidence both on the heavy
disease burden of non-bacteremic pneumonia among older adults and recent evidence confirming
the efficacy of PCV13 in the prevention of pneumococcal pneumonia among older adults
(Pilishvili & Bennett, 2015). In response to these guidelines, Medicare Part B reimbursement
began to allow for an initial pneumococcal vaccine for beneficiaries, then a second, and
different, pneumococcal vaccine 12 months after administration of the first (CMS, 2014).
Despite these guideline changes, many small, independent/ semi-independent primary
care practices, have found that they are unable to offer vaccines to their patients due to the
existence of financial barriers. Because of the financial commitment required in the purchase
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and storage of vaccines, combined with the complicated billing structure and insufficient
reimbursement, each vaccine administration represents a potential financial loss for these
practices.
Implicit in this project are several concepts both at the core of Advance Practice Nursing
and relevant to the current healthcare policy and finance reform debate: the reduction of overall
healthcare costs by investing in preventative services and the impact of public policy on
healthcare delivery. There is a plethora of evidence indicating that certain preventative services
decrease morbidity and mortality, and thus act to decrease overall healthcare costs, and
vaccination is one such instance. The role of vaccination in insuring population health and
reducing overall healthcare costs is well known and accepted, yet despite this knowledge adult
vaccination efforts lag far behind similar efforts aimed at pediatric vaccination and Healthy
People 2020/ Healthy Vermonters 2020 goals (HHS, 2010).

3
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B. Rationale/support for importance of project
The overarching rationale for this project is the financial and quality of life benefits
offered by increasing the rate of immunization against pneumococcal disease in adults ≥65, a
population who remains at the highest risk for severe illness due to pneumococcal disease. There
is an accumulation of evidence over the last decade on the cost effectiveness of vaccination
against pneumococcal illness, this is largely due to the estimated 7 billion dollars annually
associated with treatment of invasive pneumococcal disease (IPD) among patients ≥65 in the
U.S. (Thomas, et al., 2012).

Rozenbaum, et al., in a 2015 study, found that the per capita incidence of severe
pneumococcal illness among those ≥65 years was 881 per 100,000 individuals, while the overall
average prevalence was 295 per 100,000 individuals (Rozenbaum, et al., 2015).
A further consideration is the role of pneumococcal vaccination in the reduction of
antibiotic resistant S. pneumoniae strains. The CDC estimates that as many as 30% of cases of
severe pneumococcal disease involve antimicrobial drug resistant bacteria, a fact which makes
them both more difficult and more costly to treat (CDC, 2015). This is reflected in the data on
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relative length of hospitalization for antibiotic resistant versus sensitive bacteremia strains, with
the average length of stay for patients with penicillin-resistant bacteremia at 15.8 days compared
to 12 days for those with penicillin-sensitive strains, representing a 32% longer stay for those
with antimicrobial drug resistant strains (CDC, 2015).
The CDC’s Emerging Infections Programs (EIPs), the entity charged with the task of
tracking pneumococcal disease epidemiology in the United States, has reported a dramatic
decline in pneumococcal disease since surveillance began in the 1990s. This decline is largely
due to the introduction of conjugate vaccines, PCV7 and PCV13, to U.S. childhood and adult
vaccine schedules (Moore & Whitney, 2015). Additional and more troubling findings of EIPs
include the continued rise of antimicrobial drug resistant disease strains in response to
inappropriate antibiotic use and alterations in the prevalence of disease serotypes in response to
widespread vaccination, with the observed increased prevalence of serotypes not included in
current vaccine formulations (Moore & Whitney, 2015). These findings act to remind us that
disease prevention and treatment is a dynamic rather than static process, and one that requires
constant observation and response.
Though difficult to accurately quantify, conservative estimates suggest more than a
million cases of pneumococcal pneumonia annually in the U.S., with mortality occurring in 5-7%
of cases, the highest mortality rates being among adults ≥65. Invasive pneumococcal disease
(IPD) which includes meningitis and bacteremia, or sepsis, is far less prevalent than
pneumococcal pneumonia but carries a mortality rate over 20- 25% in those ≥65 years. Further,
pneumococcal meningitis results in death in one third of infected individuals, with those who
survive often suffering serious, chronic manifestations of the disease. While mortality rates for
pneumococcal bacteremia are lower, in the range of 20% of those affected, treatment of
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pneumococcal bacteremia often requires an extended period of hospitalization and ongoing
treatment following acute hospitalization.
Ozawa, et al. estimate the economic burden associated with the treatment of the sequelae
related to pneumococcal meningitis over a lifetime to be approximately $57.3 million (Ozawa, et
al., 2016). Further, Ozawa et al. estimated that the total economic burden from all vaccinepreventable diseases was approximately $9 billion in 2015, with a plausibility range of $4.7–
$15.2 billion. They further estimate that unvaccinated individuals are responsible for nearly 80%,
or $7.1 billion, of those costs (Ozawa, et al., 2016).

(Ozawa, et al., 2016)
A 2010 study by Weycker, et al. estimated the overall direct economic burden of
pneumococcal disease among US adults aged ≥50 years to be $3.7 billion with an additional cost
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of $1.8 billion in indirect costs related to wage and productivity losses attributed to the large
proportion of those ≥50 years active in the workforce (Weycker, et al, 2010). A 2012 study by
Thomas, Ryan, et al. conservatively estimated the annual cost of pneumococcal pneumonia
requiring hospitalization at > $7 billion among Medicare beneficiaries age ≥ 65 (Thomas, Ryan,
et al., 2012). They calculated the age-adjusted annual cumulative incidence to be 47.4 per 1,000
among Medicare beneficiaries, with those requiring hospitalization costing an additional $15,682
in treatment costs in the year following hospitalization (Thomas, Ryan, et al., 2012).
Efficacy of Vaccines in the Prevention of IPD

Blue bars represent overall IPD incidence.
Orange bars represent IPD incidence caused by serotypes included in the PPSV23.
Gray bars represent IPD incidence caused by serotypes included in the PCV13.
The above graph illustrates the impact of the introduction of pneumococcal vaccine on
the incidence of invasive pneumococcal disease (IPD) among U.S. adults ≥ 65 years from 19982015. The overall IPD incidence declined from 59 cases per 100,000 in 1998 to 23 cases per
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100,000 in 2015. IPD caused by serotypes included in the PPSV23 vaccine declined from 51
cases per 100,000 in 1998 to 13 cases per 100,000 in 2015, while IPD serotypes covered by the
PCV13 vaccine declined from 44 cases per 100,000 in 1998 to 5 cases per 100,000 in 2015
(CDC, 2017).
Stoecker, et al. reported that the addition of one dose of PCV13 to the vaccine schedule
for a cohort of adults ≥65 years amounted to $62,065 per quality-adjusted life year gained. A
figure which rose to $272,621 per year after 6 years due to projected herd protection offered by
adding a dose of PCV13 to the adult vaccine schedule (Stoecker, et al, 2016).
C. Relationship to advanced nursing practice
The purpose and execution of this project encompasses many of the Advance Practice
Nursing core competencies including those of Scientific Foundation, Quality Improvement,
Practice Inquiry, Technology and Information Literacy, Policy and Health Delivery System
Competencies.
This project employed Scientific Foundation and Quality and Practice Inquiry
Competencies by developing new practice protocols directly rooted in the integration of theory,
research and practice. While time consuming, the process of developing this project resulted
from a critical assessment of overall practice and patient population needs, the analysis of
practice specific data and research into current evidence based strategies, developed to improve
clinical practice and patient outcomes. Research on the larger financial and public health
implications of the problem of low vaccination rates, current evidence based tools and strategies
aimed at improving vaccination rates, the specific barriers faced by small, independent practices
all with the goal of improving the efficacy and cost effectiveness of clinical practice and

8
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increasing the delivery of services to a high risk patient population thereby improving patient
outcomes.
Implicit in this project is the examination of the direct impact of public policy and
finance decisions on the delivery of services and quality of patient care, as such, an
understanding of the complex interdependence of policy decisions and clinical practice
demonstrates achievement of Policy Competencies. Similarly, Health Delivery System
Competencies are demonstrated in the exploration of the larger context and existing resources to
improve the delivery of care to patients of the practice.
D. Contribution the project will have on intended recipient and anticipated benefits which
may result from project completion.
The most significant contribution this project will accomplish is increasing the number of
ABPC patients ≥ 65 who receive the recommended pneumococcal vaccines, thereby increasing
the relative health and quality of life of those patients and decreasing overall mortality and
healthcare costs. The additional benefit in achieving this end, is to offer ABPC a practical and
cost neutral solution to achieving more widespread vaccination among this patient population.
By achieving this end, this project would add to current the body of research on practical
methods of increasing vaccination rates among older adults and, more specifically, doing so in a
way that is cost effective for small, independent practices.
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Chapter II: Review of Literature
A. Context for proposed project
As outlined above, the evidence supporting the efficacy of vaccines, as well as the
cost effectiveness of vaccination against pneumococcal illness is undeniable, yet current
pneumococcal vaccination rates among adults ≥65 years are well below the goal set in
Healthy People 2020. Much research has focused on increasing vaccination rates through the
development of immunization campaigns or “toolkits”, many of them with great success.
While there is discussion of the financial burden on practices associated with offering
vaccination services, there is little in the existing literature as far as solutions for increasing
vaccination rates in small, independent primary care practices who cannot afford to offer
vaccination. For such practices, the potential financial losses associated with stocking and
administering vaccines are prohibitive and, as such, patients of these practice often go
without recommended vaccines.
Vaccine/
Tradename/
HCPCS Code

Dose/ Pack

CDC
Contract**
cost/ dose

Private
sector cost/
dose

Medicare B
2017
reimburse
ment***

Manufacturer

Prevnar 13™
Pneumococcal 13-valent
0.5mL/ IM 90670*

10 pk single dose
syringes

$96.56

$169.11

$192.64

Pfizer

Pneumovax®23
(Polysaccharide-23 Valent)
0.5mL/ SQ/ IM
90670*

10 pk single dose
syringes or vials

$26.15

$86.71

$98.85

Merck

*Practices are also reimbursed separately for administration of the vaccine: Administration Code: G0009, Diagnosis
Code: Z23
**Contract prices are available to programs that receive CDC immunization grant funds (eg. state health
departments, some urban immunization projects, etc.) and private providers cannot directly purchase vaccines
through CDC contracts.
*** Medicare Part B payment allowance limits for covered vaccines are 95% of the Average Wholesale Price
(AWP) as established by the compendia, from prices reported to the CDC by vaccine manufacturers annually.
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As is evident from the above table, practices are in a position of an initial cash outlay of
$1691.10 for 10 vaccines, assuming vaccines are purchased at the stated CDC cost. If the
practice were able to administer and bill for all those doses prior to the expiration date they
would receive $1926.40 in reimbursements, plus reimbursement for the administration.
However, in the event that they did not administer those vaccines before expiration, or if some or
all doses perished due to power outage or equipment failure, then the practice would simply lose
that portion of their investment and for many small, independent practices operating on very
tight margins, this is a substantial loss.
Furthermore, calculating the total cost of administering vaccines must include provider/
staff time required for counselling, administration, inventory management and documentation,
equipment costs associated with vaccine storage and opportunity costs of purchasing and storing
vaccines. These costs considered against the reimbursement received for administered vaccines
often amounts to a net loss for many small, independent adult practices.
Costs associated with vaccine administration

Vaccine purchase

Vaccine storage

Vaccine
administration

Ordering, tracking inventory and establishing payment terms
Capital required for purchase
Supplies: sharps, syringes, gloves, alcohol pads, VIS handouts,
etc.
Opportunity cost in having resources tied up in vaccine
inventory
Refrigerator/freezer
Temperature monitoring devices
Time/ labor required for temperature monitoring and recording
Backup power or storage plan in case of power failure
Insurance costs for coverage of vaccine inventory
Time/ labor required for: verification of vaccine status, patient
education, time involved in vaccine administration and
documentation
Labor costs to order, track, and maintain supply
Training required for ordering, storing, assessing, administering,
billing and coding of vaccines.
Billing and coding across various public and private payors

PNEUMOCOCCAL VACCINE PROTOCOL IN ADULT PRIMARY CARE

12

Challenges in purchasing adult vaccines
• Newer vaccines, like PCV13 are substantially more expensive than older vaccines
• Pricing variation: small practices can pay over 3 times the price of other, larger
organizations due to lower negotiated, often confidential, prices
• No federal vaccine purchase program exists for adults ≥ 65.
• Adult vaccine providers have smaller economies of scale than pediatric providers

Patients of practices that do not offer vaccines must exercise initiative by seeking
vaccination services from external vaccinators such as retail pharmacies, or other institutions,
and, not surprisingly, patients of these practices are vaccinated at significantly lower rates than
those of practices offering in house vaccination. Changes to state laws allowing for pharmacist
administered immunization offers a viable solution for small primary care practices struggling to
provide vaccination services, yet there are certain obstacles inherent in this model of vaccine
delivery. Chief among these obstacles is the issue of documentation: these immunizations are
very often not reported back to the patient’s Primary Care office and subsequently are never
entered into that patient’s Electronic Medical Record (EHR). The frequent occurrence of
pharmacies’ failure to document vaccinations, combined with other factors, like that of
healthcare received outside the state, due to the maintenance of dual residences, providers often
lack an accurate record of patients’ immunization history.
The problem of undocumented vaccinations makes it difficult for practices to determine
which patients have had what vaccines and when, a problem that is especially troubling when
approaching pneumococcal vaccines, given the complicated nature of the pneumococcal vaccine
schedule and the specificity of payor reimbursement rules. While a second dose of the same
vaccine is not harmful to the patient, it’s likely that this re-vaccination will not be reimbursed by
Medicare or other payors, so in such cases, the medical practice would absorb the cost of this
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second vaccination.
B. Current research: major themes, discussion and critique of the literature:
Vaccine efficacy and Cost effectiveness of vaccination:
While multiple studies have demonstrated PPV23’s efficacy in protecting patients against
invasive pneumococcal disease, with studies showing PPSV23 to be 50–85% effective in
preventing IPD in healthy adults, conflicting data exists as far as its efficacy in preventing
pneumococcal pneumonia (CDC, 2015). Recent studies have found that the influence of PPV23
on community acquired pneumonia (CAP) could be contingent on the amount of time since the
vaccination and could be more protective in subsets of older patients who are moderately ill or
>65 years (Aliberti, et al., 2014). Rodriguez, et al., in a 2016 study, found that 74% of the
serotypes associated with bacteremic disease were included in PVC13, and 83% of the serotypes
were included in PPV23 (Rodriguez, et al., 2016).
Polysaccharide vaccines (PPVs) contain purified and slightly modified capsular
polysaccharide antigens, because of this they are only able to elicit a T-cell independent immune
response. Alternately, the capsular polysaccharides in conjugate vaccines (PCVs) are conjugated
with a carrier protein, for example, PCV13 serotypes are conjugated to a nontoxic mutant of
diphtheria toxin (Principi & Esposito, 2016). By introducing more complex antigens, PCVs
produce a T-cell dependent immune response, which also produces mucosal immunity and
suppresses colonization (Aliberti, et al., 2014). A conjugate vaccine is generally expected to have
benefits over a polysaccharide vaccine due to its ability to elicit a T-cell-dependent response in
terms of affinity, maturation of antibodies with repeated exposure, induction of immunological
memory and long-lasting immunity (Aliberti, et al., 2014). Thus, the bulk of research comparing
the immunogenicity of the two vaccines has shown that PCVs have higher humoral
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immunogenicity and induce a stronger cell-mediated immunity (Principi & Esposito, 2016).
A 2016 study demonstrates the efficacy of the pneumococcal conjugate vaccines, like
PCV13, by examining the impact of PCV7 uptake in the pediatric population on the prevalence
of the pneumococcal serotypes targeted by that vaccine in the local adult population (Pingali, et
al., 2016). Pingali, et al. found an inverse correlation between the prevalence of pneumococcal
serotypes included in PCV7 in adults and vaccination with PCV7 among the pediatric population
(Pingali, et al., 2016).
Since the FDA licensed PCV13 for use among adults ≥50 in 2011, the incidence of
invasive pneumococcal disease (IPD) has declined by 12-32%, with IPD caused by strains
included in PCV13 declined by 58-72% among adults (Moore et al., 2015). Further, it is
estimated that over 30,000 cases of IPD and more than 3,000 deaths were prevented in the three
years following the introduction of PCV13 into the adult vaccination schedule (Moore et al.,
2015).
VACCINE

SEROTYPES

YEAR
INTRODUCED

23-valent pneumococcal
polysaccharide* vaccine
Pneumovax23® (PPSV23)

1, 2, 3, 4, 5, 6B, 7F, 8, 9N,
9V, 10A, 11A, 12F, 14, 15B,
17F, 18C, 19A, 19F, 20,
22F, 23F, and 33F

1984

• Adults ≥65 years
• Individuals ≥2 years w/
chronic illnesses

2010

• Children <5 years old

2012

• Immunocompromised
Adults ≥19 years

2014

• Adults ≥65 years

2000

• Children <5 years old

Pneumococcal 13-valent
conjugate** vaccine
Prevnar13® (PCV13)
Pneumococcal 7-valent
conjugate vaccine (PCV7)

1, 3, 4, 5, 6A, 6B, 7F, 9V,
14, 18C, 19A, 19F, and 23F

4, 6B, 9V, 14, 18C, 19F, and
23F

RECOMMENDATIONS

* Polysaccharide vaccines are made up of sub-units of polysaccharides from the cell wall of targeted bacteria.
** Conjugate vaccines contain cell walls polysaccharides from targeted bacteria, chemically linked to protein subunits. This changes the immune response from T-cell independent to T-cell dependent, resulting in increased
immunogenicity and making them more potent vaccines.

Provider Barriers to Vaccination:
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Among the most prominent themes in current research surrounding adult vaccination is
the topic of “barriers” to widespread immunization of adults, especially in comparison to the
undeniable successes of childhood immunization campaigns. Factors considered barriers by
providers include complexities of billing and inadequate reimbursement for vaccination by
public and private insurers, limited funding for vaccination of uninsured adults, costs associated
with purchasing and maintaining vaccine stock, time constraints presented by the number of
preventative services and health screening recommendations for adults at healthcare visits and
limited awareness among the public about adult vaccinations (Bridges, et al, 2015).
In a 2016 study, researchers Hurley, et al. found that, while 80% of providers surveyed
considered pneumococcal vaccine as “very important” for a hypothetical patient 67-year-old,
they report the existence of barriers to vaccinating adults that limit their ability to provide
vaccines to their patients (Hurley, et al., 2016). Hurley, et al. identified a number of problems
and barriers relating to the delivery of adult vaccines in the primary care setting: inconsistent
assessment of vaccination status, failure to stock recommended vaccines, inadequate insurance
reimbursement of vaccine administration, the financial burden of presented by up-front
purchasing of vaccines, and the inconsistent nature of communication and documentation of
immunizations administered by outside vaccinators (Hurley, et al., 2014). Another study by
Bridges, et al. noted that providers consistently cited the prohibitive cost of providing
vaccination services, inadequate or inconsistent payment for vaccine services and acute medical
care taking precedence over preventive services as the greatest barriers to vaccination (Bridges,
et al, 2015).
A 2012 survey of primary care providers reported the most cited barriers to vaccination
were financial in nature, including lack of adequate reimbursement, difficulty determining

PNEUMOCOCCAL VACCINE PROTOCOL IN ADULT PRIMARY CARE

16

insurance coverage for vaccination and the upfront costs associated with purchasing vaccines
(Bridges, et al, 2015). Hurley, et al. also cite the financial risk associated with the outlay of
resources required to stock vaccines in the primary care setting and the potential loss due to the
perishable nature of vaccines (Hurley, et al, 2014). Reimbursement issues are a consistently
noted barrier for providers with the complexities in billing and insurance coverage for vaccines
(Bridges, et al, 2015).
Hurley, et al. found that providers in small, private practices were particularly affected by
financial barriers and were shown to assume greater financial risk in stocking expensive vaccines
(Hurley, et al., 2014). Practices reporting greater financial barriers shared several common
characteristics: a private practice status, having fewer than 5 providers and having a high
proportion of patients with Medicare Part D. Further, they found regional differences with
providers in the South, Midwest and family practitioners in the Western U.S. reporting increased
financial barriers to providing immunization services (Hurley, et al., 2014).
A substantial barrier reported by providers was time constraints due to the time burden
posed by acute patient care and the existence of other preventative care they perceive as taking
precedence over vaccination services, with providers noting the time consuming nature of
vaccination services not the least of which is the time required for regular assessment of patient
immunization status (Hurley, et al, 2014). However, despite stated scarcity of time, the majority
of providers included in the study still believed it was the primary care provider’s responsibility
to ensure their patients receive recommended vaccinations (Hurley, et al., 2014). Further, Hurley,
et al. found that Medicare preventive visits, which provide an ideal opportunity for the delivery
of vaccination and other preventive services, remained largely underutilized (Hurley, et al.,
2016).
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Patient Barriers to Vaccination:
Patients consistently report not receiving vaccine recommendations at provider visits, and
this is despite the well established evidence showing receipt of a provider recommendation is a
key predictor of vaccination. A 2008 study Johnson, et al. found that 79-85% of adult patients
stated they were likely to receive a vaccination if their healthcare provider recommended it
(Johnson, et al., 2008). A 2010 survey of consumers and providers conducted by the National
Foundation for Infectious Diseases found that 88% of consumers reported that a strong
recommendation from their physician would increase the likelihood of receiving a vaccination
(Bridges, et al, 2015). A Canadian study examining the fact that fewer adults ≥65 years received
pneumococcal vaccines than receive annual influenza vaccines found that being offered the
vaccine by a health care provider had the strongest correlation with a patient receiving a vaccine
(Schneeberg, et al., 2014). Similarly, an international meta-analysis by Kohlhammer, et al. found
that provider recommendation played a central role in predicting pneumococcal vaccination,
noting that the primary reason for not being vaccinated was “lack of information” (Kohlhammer,
et al., 2007). While 87% of providers surveyed reported discussing vaccines with their patients,
only 47% of patients recalled discussing vaccines, other than seasonal influenza vaccine with
their provider (Bridges, et al, 2015).
Lack of patient knowledge or awareness of adult vaccination recommendations is another
consistently cited factor impacting adult vaccination. A 2006 consumer survey found that 82% of
consumers believed it was important to keep up with immunizations but among the most often
cited reasons patients did not seek vaccination was the belief that vaccination was unnecessary or
not indicated for healthy adults (Bridges, et al, 2015).
A 2014 study by Sabapathy, et al. found that 44 % of the 53,249 unvaccinated older

PNEUMOCOCCAL VACCINE PROTOCOL IN ADULT PRIMARY CARE

18

adults studied had at least one acute care visit over a one year period (Sabapathy, et al,. 2014).
This number is significant in that it represents opportunities for immunization for patients that
may not engage in regular health maintenance.
Immunization Toolkits
Despite these challenges, a number of systems level interventions have been
demonstrated to substantially improve adult vaccine rates in the primary care setting. Critical to
the success of such programs is routine assessment of patients’ vaccination status during all
clinical encounters and ensuring patients either receive the recommend vaccines on site, or are
referred for to outside sources for vaccine administration (Bridges, et al, 2015).
A 2014 study by Turner, et al. developed a multifaceted, nurse led intervention program
to address knowledge deficits and increase vaccination rates. These interventions consisted of
incorporating standing protocol vaccine orders, educating nurses on current ACIP guidelines
with weekly in-service trainings, creation of a script for nurses to aid them in discussing the
importance and benefits of immunizations, displayed of educational posters within the practice
and created a vaccine reminder system (Turner, et al, 2014). In identifying barriers within
individual practices and formulating strategies to address those barriers, this study recognized the
critical role of nurses in increasing vaccination rates through patient education and incorporating
vaccine tracking and administration into the flow of routine clinical care (Turner, et al, 2014).
Norwalk, et al. developed the 4 Pillar Toolkit, a system designed to encourage
vaccination uptake in the primary care setting. Like Turner’s and several other vaccination
strategies, the 4 Pillar Toolkit employs a standing order program (SOP), which is a blanket
document empowering non-provider staff to assess immunization status and administer vaccines
without an individual order from a provider. A number of other elements are commonly featured
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in primary care immunization toolkits, including a systems level intervention which incorporates
vaccination into the standard workflow, staff education around current ACIP guidelines and the
importance of vaccination in disease prevention, creation of a patient education/ awareness
campaign and the creation of provider/ staff and patients reminder systems (HHS, 2016).
A 2015 Lebanese study conducted by Ghadieh, et al., compared the impact of several
reminder methods, both with and without patient education, on pneumococcal immunization
rates in the primary care setting. Authors compared a short phone call, a short text message or an
email, each with and without patient education and analyzed the relative efficacy of each system.
Ghadieh, et al. found that the short phone call method yielded a 16.5% response rate, while a
short sms-text produced a 7.2% increase in vaccination and the e-mail method was associated
with a 5.7% increase. Researchers also found that there was no statistically significant difference
between those who received patient education and those who did not. Given the time and staff
resources required to execute reminder phone calls, researchers concluded the both sms-text and
e-mail reminders provided a feasible and sustainable model to increase pneumococcal
vaccination rates in a primary care setting (Ghadieh, et al., 2015).
A 2015 article in AAFP addresses the financial considerations for primary care practices
around providing recommended vaccinations and offers suggestions to improve the financial
viability of providing these vaccines. The author’s small practice, including three physicians and
two nurse practitioners, has achieved steady revenue from immunizations (Loehr, 2015). This
was achieved by systematically comparing prices and purchasing vaccines at the lowest available
cost, often directly from pharmaceuticals is essential for increasing profitability. Additionally,
thorough and appropriate coding for vaccination services results in maximum reimbursement,
this includes billing for the vaccine itself, each immunization administration, and includes a
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diagnosis code, a National Drug Code (NDC), and a CPT code (Loehr, 2015).
Vaccine Documentation:
A 2011 study conducted by Hurley, et al. found that 79% of providers had concerns about
the time and effort required in referring patients to outside vaccinators and expressed concern
over what they deemed inadequate documentation by external vaccinators (Hurley, et al., 2011).
Further, many providers included the Hurley, et al. study described communication between the
primary care office and alternate vaccinators as “suboptimal”, with 48% of family medicine
physicians reporting that it was “moderately/very difficult” to determine an adult patient’s
vaccination status other than that of seasonal influenza vaccinations (Hurley, et al., 2014).
Rolnick, et al. sought to perform a comprehensive assessment of the validity of selfreported adult vaccination status for the eight most common adult vaccines by comparing
vaccines patients recalled having received and compared that information to the patients
electronic health record (EHR) (Rolnick, et al., 2013). Variation was found across vaccines and
Nowhere is poor patient recall and inadequate immunization record keeping more pertinent than
when considering pneumococcal vaccines given the complex, multi-variant guidelines around
the timing, sequence and interval between vaccine administrations (Rolnick, et al., 2013).
State Immunization Registries:
State immunization registries, which, in theory collect and consolidate vaccination data
from multiple health care providers, external and community vaccinators in a central database
are another critical tool for increasing adult vaccination. State immunization registries are
potentially a valuable resource to overcoming communication barriers between primary care and
external or community vaccinators. The ability to access collective vaccination information via
state registries acts to prevent unnecessary vaccination, billing and reimbursement problems and
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helps to avoid missed opportunities for vaccination (CDC, 2011).
Created to overcome the problem of lack of documentation, state registries, including the
Vermont Immunization Registry, attempt to capture undocumented vaccinations by mandating
the reporting of all vaccinations administered in the state to a central Department of Health
managed registry. However, despite the presence of a state law requiring pharmacies to report all
vaccinations administered to the Vermont Immunization Registry, as of August 2016 only 34%
of pharmacies in Vermont were sending immunization data to the IMR, though it is important to
note that not all pharmacies in Vermont administer vaccines (VDH, 2016). Further, pharmacies
that report to the IMR do so in monthly batch files, as a result, this data may take as long as 30
days to propagate in the IMR (VDH, 2016).
Recent research by Stockwell, et al. focused on the implementation of bidirectional
information sharing between EHRs and immunization registries and its impact on immunization
coverage (Stockwell, et al., 2016). Researchers found the implementation of bidirectional
information sharing lead to significant improvements in pediatric immunization coverage, a
reduction in over-immunization for adolescents, a decrease from 8.8% to 4.7% and increased
accurate documentation of immunizations from 75% to 81.6% (Stockwell, et al., 2016).
Wilson, et al., point out the limitations of state registries in the context of an increasingly
itinerant population, suggesting that mobile technologies may help to mitigate some of the
challenges multiple state registries present, though they do so with a set of problems of their own
including privacy of data, access, and equity (Wilson, et al., 2017).
Role of Pharmacies in Vaccine Administration:
A 2016 Vermont Department of Health brief acknowledges that changes to state law and
Medicare reimbursements have made pharmacies key players in increasing access to adult
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vaccines in Vermont with 14,305 pharmacist administered immunizations reported to the IMR
between July 2015 and June 2016 (VDH, 2016). However, likely due several factors, only 7% of
all Pneumococcal vaccines reported to the registry are given in the pharmacy setting, compared
to 12% of Herpes Zoster vaccines (VDH, 2016).

(VDH, 2016c)

A recent study by McConeghy and Wing found that while changes to state laws allowing
pharmacists to administer vaccines resulted in a six-fold increase in the number of pharmacist
administered influenza vaccinations, this increase did not correspond to a significant increase in
the overall number of adult vaccinations administered (McConeghy & Wing, 2016). This
research suggests that those who seek vaccination services from pharmacists would likely have
been vaccinated anyway, thus the value of pharmacy based vaccination rests in providing a
convenient and flexible method of obtaining these services but not in expanding vaccination to
those previously not inclined to seek them (McConeghy & Wing, 2016).
Singhal, et al sought to determine whether the direct medical costs paid for adult
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vaccination differ depending on the setting, focusing on costs paid in an inpatient/ outpatient
medical setting versus those paid in the pharmacy setting (Singhal, et al., 2014). Costs included
in this analysis by Singhal, et al. considered the cost of the vaccine itself, vaccine administration
and, if applicable, a dispensing fee or charge for the office visit. Singhal, et al. found the average
direct costs paid per adult vaccination were 16%-26% higher in the primary care setting and
11%-20% higher in alternate inpatient or outpatient medical settings compared to vaccines
administered in the pharmacy setting (Singhal, et al., 2014).
There is little or no available research on the feasibility of small, understaffed primary
care practices offering adult vaccination services or on the problem of low vaccination rates in
practices who do not offer vaccination services. The value in this project is that it requires no
cash outlay for a practice, very little time for office staff, no cost to patients and makes use of an
existing resource by utilizing pharmacies offering vaccination services. If this protocol proves
effective it will allow more patients to be vaccinated, those vaccinations will be documented and
little or no capital will be required for it’s launch.
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Chapter III: Method
A. Procedures and/or process involved in project completion
In 2014 the National Vaccine Advisory Committee released updated guidelines for Adult
Immunization Practice, which was based on the accumulation of evidence on common barriers to
adult vaccination and strategies proven effective for increasing adult vaccination rates (National
Vaccine Advisory Committee, 2014). The NCIP’s “Standards for Immunization Practices”
recommends that all healthcare providers routinely assess patients vaccination status during
every clinical encounter, strongly recommend indicated vaccines, offer vaccinations at the same
visit or, if the vaccine is not offered by the provider, refer the patient to outside vaccinator, and
finally, that vaccinations are documented in state registry systems when available (National
Vaccine Advisory Committee, 2014).
Based on these guidelines, first a protocol was developed for use at ABPC and later a
vaccination clinic was established with the goal of increasing vaccination among patients≥65
This project involves assessing the pneumococcal vaccination status of each ABPC
patient ≥65, those patients ≥65 with an appointment scheduled on days designated for this
intervention will be approached by the primary investigator and asked to verify their vaccination
history.
This project is intended to assess vaccination status of ABPC patient ≥65 and, if
vaccination is indicated, provide them with a written recommendation to seek vaccination from
an external vaccinator or pharmacy. Those patients ≥65 with an appointment scheduled on days
designated for this intervention will be asked to verify their vaccination history. Patients will be
educated about current pneumococcal vaccination recommendations and asked if, where and
when they may have received a pneumococcal vaccination outside the practice/ UVM Medical
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Center. If patient reports an unrecorded vaccination, the investigator will then call the pharmacy
or institution to verify vaccine type and administration date, and his/ her EHR will be updated to
reflect an accurate vaccine history. For those patients who need additional vaccinations, the
investigator will determine the proper PNU vaccine schedule for that patient and a verified
“vaccination order” will be furnished to the provider to dispense to the patient. This form will
direct patients to present this form to any pharmacy offering Prevnar13®/ Pneumovax23® for
vaccination.

As a necessary component of the project a list of all ABPC patients ≥ 65, their
vaccination history and the recommended vaccine schedule based information currently recorded
in PRISM was compiled. This data was recorded in an excel spreadsheet.
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The rationale for these methods is to catch vaccinations that patients have had which are
not recorded in PRISM. So, while not always an accurate representation of the patient’s
vaccination history, the information reflects what is recorded the patient’s EHR, and allows a
method to catch and correct inaccuracies in documentation and insure that each patient has both
the recommended PNU vaccines. Similarly, while external vaccinations do not require an order/
or provider signature, this form was developed to serve the duel purpose of acting as a formal
“provider recommendation” of the specified vaccination and to serve as documentation of
vaccination by outside vaccinators, given the problem of insufficient documentation of pharmacy
administered vaccines which are rarely documented in a patient’s medical record.
Outcomes were evaluated by collecting all responses received, including vaccine
documentation forms submitted by external vaccinators, forms reporting previous pneumococcal
vaccine administration. The number of completed and returned vaccination forms, number of
forms documenting previous vaccinations and number of incomplete/ unreturned forms will be
assessed in relation to the number of patients ≥ 65 seen over the 10 days of the intervention. The
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reasons for incomplete forms will be examined for common themes and provider/ staff feedback
will be used to explore ways in which the process might be streamlined or the efficiency of the
system.
Vaccination clinic outcomes were measured and analyzed based on the number of
patients contacted, the type of contact and the response to contact. Overall response rates will be
calculated for each subcategory of patient contact type.
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Chapter IV: Evaluation and Discussion
A. Achievement of project objectives reflect results of evaluation
In the final phases of this project, an alliance was developed between the practice and a
local independent pharmacy with the goal of vaccinating ABPC patients 65 and older. A single
trial vaccination clinic was it established in collaboration with the Vermont Family Pharmacy
wherein patients were contacted by phone by the primary investigator, informed that they may be
due for one or more pneumococcal vaccination and asked if they would like to schedule an
appointment for that vaccination. The pharmacy was responsible for ordering administering and
billing for vaccinations, while the practice was responsible for calling patients 65 and older in
need of a pneumococcal vaccination. The pharmacy then reported all administered vaccines back
to ABPC. There was no release of protected health information and the Vermont Family
Pharmacy only had access to the names and phone numbers of those who consented to
scheduling an appointment at the vaccination clinic.
Patients targeted for the initial pneumococcal vaccine clinic were unvaccinated patients at
highest risk for pneumococcal disease, including those with a diagnosis of chronic obstructive
pulmonary disease (COPD), asthma or those documented as current cigarette smokers.
Patients were called by the primary investigator and given a brief summary of
pneumococcal vaccination recommendations and asked if they would like to schedule an
appointment to receive the needed vaccination. Those patients wishing to receive vaccination
were scheduled on a single afternoon in July in 10 minute increments. Patients were asked what
type of insurance they had and their mailing address was verified so that a brief vaccination
screening questionnaire and consent form could be mailed to their home, which was to be
returned at the time of vaccination.
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A non-specific message was left for those patients who did not answer the call from the
primary investigator. The message was as follows:
“This is Marina Ecklund calling from Appletree Bay Primary Care for ________. I am
calling because our records show you may be due for one or more pneumococcal
vaccinations. ABPC, in conjunction with Vermont Family Pharmacy, is offering a
pneumococcal vaccination clinic on July 13 from 1:30-5 PM. This vaccination is fully
covered by Medicare and most private insurance, with no out of pocket cost to patients. If
you would like to schedule an appointment for a vaccine, or already received a vaccine
that we do not have record of, please call her office back at 863 1313. Thank you.”

Those patients reached by phone were asked for by first name, I then identified myself
and stated I was calling on behalf of Appletree Bay Primary Care, patients were then asked to
verify their name and date of birth. After the patient identity was verified, the patient was told
that according to ABPC’s records, he or she was due for one or more pneumococcal vaccines.
There was a brief educational intervention whereby patients were informed currents guidelines
around pneumococcal vaccination for patients 65 and older, as well as, the risks associated with
pneumococcal illness in older adults with certain respiratory conditions. Patients were then
informed of the past pneumococcal vaccinations Appletree Bay Primary Care had on file for
them and asked if they had any pneumococcal vaccine administrations that remained unrecorded.
If patient had no previous unrecorded vaccinations they were asked if they would like to
schedule an appointment on the specified day to receive the recommended vaccine. If patients
agreed, an appointment was scheduled to receive specified vaccine at Vermont Family
Pharmacy, their insurance was verified as was the mailing address where they wished to receive

PNEUMOCOCCAL VACCINE PROTOCOL IN ADULT PRIMARY CARE

30

the screening and consent form used by Vermont Family Pharmacy.
Along with the consent form the patient was also sent a form letter with appointment
details, directions for appointment cancellation and contact information for Appletree Bay
Primary Care. Letters were then mailed to scheduled patients at the expense of the primary
investigator. All calls were logged as “Immunization Outreach” in the patient’s EHR and notes
detailing the contact were recorded by the primary investigator.
Of those patients contacted the majority had a positive response to the call and were
willing to schedule an appointment at the vaccination clinic. Of all the patients contacted, only
one reported he was opposed to immunization and did not wish to be contacted in future
vaccination outreach endeavors. It was discovered that those reached by phone at the time of
initial contact were much more likely to schedule an appointment than those patients who failed
to answer and instead received a message with vaccination clinic information. These patients
were much less likely to call back and schedule and appointment. This may represent a
confounding factor in that those who answer the phone, rather than letting the call go to
voicemail may also be more likely to be proactive about their healthcare.
Nature of telephone
contact

Patient Response

Proportion

Spoke to patient

Patient stated they preferred to seek recommended
vaccination at a more convenient time or pharmacy

36% (5/14)

Spoke to patient
Spoke to patient
Left message for
patient
Left message for
patient
Spoke to patient or
left message for
patient

Patient scheduled an appointment for recommended
vaccination at VFP/ ABPC clinic
Patient agreed to receive recommended vaccination at
VFP/ ABPC clinic or another time or pharmacy

57% (8/14)
78% (11/14)

Patient called back to schedule vaccination

21% (3/14)

Patient did not call back or schedule vaccination

79% (11/14)

Patients contacted who scheduled an appointment for
recommended vaccination at VFP/ ABPC Clinic

40% (10/ 28)
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Among patients who were reached and spoke directly to the primary investigator by
telephone, 78% agreed to either schedule an appointment or stated they would seek vaccination
services at another time or pharmacy. Overall, 40% of those contacted received the
recommended vaccination either at the vaccination clinic or at another time or pharmacy. Of
those patients reached by phone and spoke directly to the primary investigator 57% agreed to
schedule an appointment for the clinic, while only 21% among those who failed to answer but
instead, received a message stating that they may be due for a recommended vaccination,
informing them of the clinic and asking them to call ABPC to schedule an appointment
responded and scheduled an appointment. Two patients reported previous unrecorded
vaccinations and 7 patients stated they wished to be vaccinated at another, more convenient, time
or pharmacy. Of those reached by phone who did not schedule appointments at the vaccination
clinic due to lack of transportation to and from the clinic, asked if it was possible to schedule a
vaccination at the time of their upcoming appointment. Data pertaining to the receipt of these
vaccines was not captured, due to lack of access to the Vermont IMR.
B. Implication for practice, education, and/or research
Based on these findings, it was determined that direct patient outreach via telephone and
simultaneous scheduling of vaccinations at an organized vaccine clinic resulted in a far greater
number of vaccinations and proved to be the most effective method of increasing vaccination
rates. While the initial intervention incorporated much in the way of current data on barriers to
vaccination, it appears that facilitating the vaccine administration, rather than simply
recommending that the patient be vaccinated was critical in achieving increased vaccination rates
among this population. Based on these findings, it is recommended that future efforts targeting
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vaccination in this population should focus on direct telephone contact with patients and should
include scheduling a specific time and place for administration of the the recommended vaccine.
C. Limitations of project
Chief among the limitations of this project was the issue of small sample size. It is difficult to
draw conclusions based on the project’s findings due to the small number of patients involved in
the interventions. Because of this, future research on a larger scale is necessary to validate the
findings of this project.
Further, there were many steps that were necessary prior to the implementation of this project
around determining initial vaccinations status of the patients in question. First, a single report
detailing which pneumococcal vaccines each patient had and when/ at what age they were
administered did not exist in the electronic health record (EHR). As a result, it was necessary for
the primary investigator to create a report that included all patients in the Appletree Bay Primary
Care practice age 65 and older, along with the vaccinations they had, and the outstanding
recommended vaccines. To do this, it was necessary to compile a list of all practice patients age
65 and older and manually record the vaccinations they have received. This information was
compiled into an Excel spreadsheet and made available to providers and staff of the practice.
This information was then used to determine which vaccinations patients needed and outreach
was based on this information. This portion of the project amounted to many of hours of work.
While it was likely possible to create a report in the EHR that included this information without
manually gathering and compiling the data, the primary investigator made multiple calls to the
EHR help desk requesting assistance with no response. This complication is mentioned because
it is a problem commonly faced in the use of EHRs, those without understanding or training and
with insufficient technical support are unable to fully utilize the technology. As a graduate
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student, I had the 20-30 hours required to compile such data, but it is unrealistic for any primary
care practitioner or staff to take that amount of time away from patient care for such work.
Further, despite the importance of increasing vaccination among this vulnerable population, in
the case of vaccination, it is work which results in financial loss rather than revenue for the
practice.
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Appendices A : Adult Pneumococcal Vaccine Recommendations
The following is a four page guide to proper sequencing of the pneumococcal vaccines in adults,
based on which pneumococcal vaccines were received when, prior to age 65 (Centers for Disease
Control and Prevention, 2015).

(CDC, 2015)
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Appendices D: VDH Statistics

(VDH, 2016a)
Of note, women in the Burlington area are significantly more likely to have made a routine visit
to their doctor in the last year as compared with men (70% vs. 60%), but similar to state
averages, remain statistically similar across other demographic differences (Vermont Dept of
Health, 2016a).

Data from (VDH, 2016a)
The State of Vermont reports modest progress in reaching the goal of 90% pneumococcal
vaccination rate among adults age ≥65 from 74% in 2011 to 76% in 2015, while this average
remains significantly higher than the 2015 U.S. average rate of 71% (VDH, 2017) (CDC, 2015).
Further, the Vermont Department of Health Burlington District Office reports 79% of Burlington
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area adult residents aged ≥65 have gotten at least one pneumococcal vaccine, compared to the
Vermont statewide average of 76% (VDH, 2016a, 2017). This likely is, at least due in part, to
the relative accessibility and convenience of health care providers in the Burlington as compared
to other, more rural areas of the state.

Data from (VDH, 2016b)

(VDH, 2016b). Burlington Health District 2014-2015
BRFSS

